1-2 of 2
Harriet Harder
Close
Sort by
Journal Articles

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

Christian Buske, Eva Hoster, Martin Dreyling, Roswitha Forstpointner, Michael Kneba, MD, PhD, Norbert Schmitz, Rudolf Schmits, Bernd Metzner, Marcel Reiser, Eva Lengfelder, Bernhard J Woermann, Harriet Harder, Susanna Hegewisch-Becker, Wolfgang E. Berdel, Georg Hess, Hartmut Eimermacher, Ali Aldaoud, Manfred Planker, Michael Unterhalt, Wolfgang Hiddemann, MD
Journal: Blood
Blood (2008) 112 (11): 2599.
https://doi.org/10.1182/blood.V112.11.2599.2599
Published: 2008
Journal Articles

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Clinical Trials & Observations
Wolfgang Hiddemann, Michael Kneba, Martin Dreyling, Norbert Schmitz, Eva Lengfelder, Rudolf Schmits, Marcel Reiser, Bernd Metzner, Harriet Harder, Susanna Hegewisch-Becker, Thomas Fischer, Martin Kropff, Hans-Edgar Reis, Mathias Freund, Bernhard Wörmann, Roland Fuchs, Manfred Planker, Jörg Schimke, Hartmut Eimermacher, Lorenz Trümper, Ali Aldaoud, Reza Parwaresch, Michael Unterhalt
Journal: Blood
Blood (2005) 106 (12): 3725–3732.
https://doi.org/10.1182/blood-2005-01-0016
Published: 2005